Home
Company Info
Company Evolution
Company Profile
Management Team
Business Strategy
Corporate Governance
Media Centre
Events
Media Contact
Investor Relations
Investor Home
Press Release Archive
Company Facts Report
Broker Forecasts
Email Alerts
Trading Info
Annual & Interim Reports
Advisers & Registrars
Company Presentations
Financial Calendar
Shareholder FAQs
Contact Details
Research & Development
Preclinical Research
Selected Publications
Research Programmes
Product Portfolio
Commercialisation
Commercialisation Overview
Outlicensing
Contact Us
Glossary
Navigation menu
Discover more about Ark Therapeutics products here
Ark Therapeutics, From science To patients
Preliminary CereproŽ Phase III results meet primary endpoint
30 July 2008
EMEA Gene Therapy Working Party gives positive feedback on EG013 for foetal growth restriction
16 July 2008
Ark opens new manufacturing facility in Finland
08 July 2008
EG011 demonstrates ability to grow new blood vessels and restore heart function following heart attack
18 June 2008
Read more news stories here
2007 Annual Report published.
20 March 2008
2007 Interim Report published.
04 September 2007
Visit the Investor Relations section of the web site.
2007 Preliminary Results presentation
11 March 2008
67.75 p
Change: 0.25p
Last Trade: 21/8/2008 19:31
View share price data
Use the search form below to search our site.
Search
Download the latest Annual Report & Accounts
[1.7MB]
Keep up-to-date with product developments, investor relations information and news with our email updates.
Register here to receive our email alerts.
©2008 Ark Therapeutics Group plc. All rights reserved | Site Design and Maintenance by
3wise Internet Solutions
To view PDF files on this site, you will need Adobe Acrobat Reader.
Download it for free here.
Stats Script
Stats Script